Weekly administration of a new, long-acting basal insulin analogue might be one way to improve the treatment burden in patients with type 2 diabetes. A phase 2 study randomised 237 adults to either once-weekly subcutaneous insulin icodec plus once-daily placebo, or once-daily subcutaneous glargine and once-weekly placebo for 26 weeks. Patients were previously on stable ...
Type 2 diabetes
EASD 2020: Once weekly insulin may help T2D management
By Mardi Chapman
24 Sep 2020